ABT Jan 2025 50.000 call
| Previous Close | 54.39 |
| Open | 55.16 |
| Bid | 55.15 |
| Ask | 56.45 |
| Strike | 50.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 54.39 - 55.16 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 17 |
ZacksAbbott (ABT) Gains But Lags Market: What You Should Know
In the latest trading session, Abbott (ABT) closed at $102.82, marking a +0.8% move from the previous day.
ACCESSWIREAbbott, Real Madrid and the Real Madrid Foundation Band Together To ‘Beat Malnutrition’ Globally Through New Campaign
Abbott (NYSE:ABT), Real Madrid and the Real Madrid Foundation announced the launch of the 'Beat Malnutrition' campaign during Real Madrid's final match weekend of the 2022/2023 LaLiga season. The new campaign empowers communities to help children reach their full potential through nutrition education and malnutrition screening and furthers Abbott's partnership with Real Madrid and the Real Madrid Foundation to reduce global childhood malnutrition.
ZacksAbbott (ABT) Gains As Market Dips: What You Should Know
Abbott (ABT) closed at $102 in the latest trading session, marking a +0.29% move from the prior day.
- Reuters
Abbott accuses one of its former scientists of trade-secrets theft in US court
Healthcare company Abbott Laboratories on Tuesday sued one of its former scientists, accusing him in U.S. court of "secretly downloading" sensitive corporate files containing competitive information about nutrition products. The lawsuit in Chicago federal court alleged Roger Tyre committed "flagrant misconduct" prior to leaving Illinois-based Abbott, which sells the Ensure brand nutrition powders and shakes. Abbott said it learned of the alleged downloads of thousands of files in March.
ZacksAbbott (ABT) Reports Upbeat Cardiomems Sensor Study Result
Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.
ZacksAbbott (ABT) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Abbott (ABT) closed at $102.14, marking a -1.83% move from the previous day.
- Zacks
Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
Yahoo Finance VideoFTC investigating baby-formula makers on suspected collusion
Yahoo Finance health care reporter Anjalee Khemlani discusses the ongoing investigation by the FTC of baby-formula makers, including Abbott Laboratories, Perrigo, and Nestle, on suspected collusion.
ReutersUPDATE 3-Abbott, baby formula makers face FTC probe for potential collusion
The U.S. Federal Trade Commission (FTC) is probing whether Abbott Laboratories and other companies that make baby formula colluded in bidding on state contracts, according to a document posted on the agency's website. The FTC is looking into whether the companies "engaged in collusion or coordination with any other market participant regarding the bidding," according to the document. The Wall Street Journal was first to report the probe.
ReutersAbbott, baby formula makers face FTC probe for potential collusion
The FTC is looking into whether the companies "engaged in collusion or coordination with any other market participant regarding the bidding," according to the document. The Wall Street Journal was first to report the probe. According to the document, in 2022 the FTC began looking into potential collusion or coordination in bids to provide formula for the U.S. Department of Agriculture's Women, Infants and Children (WIC) program that provides free formula to low-income families.
- Reuters
UPDATE 1-Judge tosses out some claims in Abbott baby formula litigation
Abbott Laboratories persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination. But the judge said the parents lacked standing to sue, saying they did not show which Abbott products or lots were contaminated, or that their children experienced symptoms.
ReutersJudge tosses out some claims in Abbott baby formula litigation
Abbott Laboratories persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination. But the judge said the parents lacked standing to sue, saying they did not show which Abbott products or lots were contaminated, or that their children experienced symptoms.
- Reuters
Judge tosses some claims in Abbott baby formula litigation
Abbott Laboratories persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination. The parents said they would not have bought or would have paid less for formula but for the Abbott Park, Illinois-based company's claims that it was safe.
ZacksAbbott (ABT) Expands in Electrophysiology With New FDA Nod
Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.
- Zacks
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval
Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.
ZacksAbbott (ABT) Down 1.7% Since Last Earnings Report: Can It Rebound?
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ACCESSWIREComing Together on the Journey to End Parkinson’s
As far as epic journeys go, 1.2 miles is pretty manageable and quite lovely.
- Reuters
UPDATE 1-Abbott Labs is sued over PediaSure height claims
A New York City woman sued Abbott Laboratories on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height. In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller. The Bronx resident said that by February, after a year of two PediaSure drinks per day, her grandson was still short for his age and had become "so overweight" that she stopped buying the drinks.
ReutersAbbott Labs is sued over PediaSure height claims
NEW YORK (Reuters) -A New York City woman sued Abbott Laboratories on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height. In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller. The Bronx resident said that by February, after a year of two PediaSure drinks per day, her grandson was still short for his age and had become "so overweight" that she stopped buying the drinks.
- Zacks
Abbott's (ABT) New Pact to Advance Clinical Trials Diversity
Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.
ACCESSWIREAbbott Announces New Partnerships and Programs To Advance Its Diversity in Clinical Trials Initiative
Abbott (NYSE:ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations.
ZacksHere's Why You Should Retain Abbott (ABT) Stock For Now
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
- Zacks
Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
ZacksCigna (CI) Q1 Earnings Surpass Estimates, Ups '23 EPS View
Cigna's (CI) first-quarter 2023 results indicate a strong contribution to revenues from Evernorth Health Services and Cigna Healthcare businesses. Management currently expects adjusted EPS to be a minimum of $24.70 in 2023.
ZacksThe Zacks Analyst Blog Highlights Berkshire Hathaway, Tesla, JPMorgan Chase, Abbott Laboratories and Comcast
Berkshire Hathaway, Tesla, JPMorgan Chase, Abbott Laboratories and Comcast are included in this Analyst Blog.
